[Experience of using Reamberin for the correction of cognitive impairment and antioxidant status in the late period of traumatic brain injury]. / Opyt primeneniya preparata Reamberin dlya korrektsii kognitivnykh narushenii i antioksidantnogo statusa v otdalennom periode cherepno-mozgovoi travmy.

OBJECTIVE: To study the efficacy of Reamberin in cognitive impairment in patients associated with traumatic brain injury, taking into account its effect on the parameters of neuropsychological and antioxidant status. MATERIAL AND METHODS: We examined 45 patients aged 35 to 60 years with cognitive impairment in the late period of traumatic brain injury. The patients were divided into two groups depending on the prescribed treatment. The first main group included 25 patients with cognitive impairment who received complex therapy: Reamberin against the background of standard treatment. The second control group consisted of 20 patients with cognitive impairment who received only standard therapy. In accordance with the purpose of the study, the parameters of the neuropsychological and antioxidant status were determined. RESULTS: The analysis of cognitive disorders according to the Montreal Cognitive Assessment made it possible to establish cognitive impairments in 100% of the patients included in the study in the late period of traumatic brain injury. The introduction of Reamberin to patients contributed to an improvement in work efficiency and a decrease in the amount of time required to prepare for work in relation to control (p<0.05), an increase in the volume of auditory short-term memory in dynamics from the moment of admission to the 11th day by 1.9 times (p<0.05). The evaluation of the parameters of the antioxidant status in the late period of traumatic brain injury made it possible to establish that in patients of the main group who received Reamberin as part of standard therapy, by the end of the observation (day 11), the concentration of lipid peroxidation products was lower than in the control by 13-43%, the level of ceruloplasmin and catalase activity are higher by 14 and 15%, respectively (p<0.05), which confirms the antioxidant activity of Reamberin. CONCLUSION: It was concluded that the inclusion of Reamberin in the treatment regimen for patients with cognitive impairment in the late period of traumatic brain injury should be considered clinically justified and promising.

[Experience of using reamberin on the cognitive functions in children with epilepsy]. / Opyt primeneniya reamberina dlya korrektsii kognitivnykh funktsii pri epilepsii u detei.

OBJECTIVE: To study the efficacy of reamberin in treatment of epilepsy in children and to evaluate its effect on the cognitive functions. MATERIAL AND METHODS: The study included 51 patients with epilepsy aged 7 to 15 years. The children were divided into four groups depending on the prescribed treatment. The first study group (n=16) received intravenous reamberin once daily for 5 days in addition to carbamazepine. The second group (n=15) received intravenous reamberin once daily for 5 days in addition to valproic acid. Two comparison groups (10 patients each) received only carbamazepine or only valproic acid, respectively. Cognitive functions were assessed at admission and on the 6th day of treatment using Schulte tables (10 words). RESULTS AND CONCLUSION: Reamberin significantly increases the work efficiency by 19-21%, and workability degree by 8-12% compared with the patients of the control groups. An analysis of the effect of succinate-containing drug on auditory memory has shown that the volumes of short-term memory and long-term memory are by 1.8 times and 1.3 times, respectively, higher than those in the control groups. Thus, the addition of reamberin into the treatment of children with epilepsy should be considered clinically reasonable, and promising.

[The effect of reamberin on the antioxidant status in children with epilepsy]. / Primenenie reamberina dlia korrektsii antioksidantnogo statusa pri épilepsii u detei.

AIM: To study the efficacy of reamberin in treatment of epilepsy in children and to evaluate its effect on the antioxidant status. MATERIAL AND METHODS: The antioxidant activity of reamberin was investigated in children with epilepsy: 16 patients received intravenous reamberin once daily for 5 days in addition to carbamazepine. Patients of the control group (n=15) received only carbamazepine. The efficacy of the drug was evaluated by the levels of lipid hydroperoxides, conjugated dienes, and malondialdehyde and by the activity of the main components of the antioxidant system (ceruloplasmin, vitamin E, catalase) in the blood of patients. RESULTS AND CONCLUSION: Reamberin significantly reduces the plasma levels of lipid hydroperoxides by 16%, conjugated dienes by 12%, and malondialdehyde by 25% compared with the patients of the control group. An analysis of the effect of succinate-containing drugs on the activity of the antioxidant system components has shown that blood concentrations of ceruloplasmin, vitamin E and catalase are by 35, 14% and 15%, respectively, higher than those in the control group. Thus, the addition of reamberin into the treatment of children with epilepsy should be considered pathogenetically justified, clinically reasonable, and promising.

[THE EFFECT OF CYTOFLAVIN ON PARAMETERS OF THE LEFT VENTRICULAR SYSTOLIC FUNCTION IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION.]

The effect of cytoflavin on parameters of the left ventricular systolic function (LVSF) during acute myocardial infarction was studied in a group of 46 patients which received this drug (in addition to standard therapy) intravenously as 20 mL of Polysan solution (St. Petersburg, Russia) diluted in 250 mL of 5% glucose solution once a day 30 min before coronary artery recanalization. The control group of 60 patients received only standard therapy. The drug effectiveness was evaluated in terms of LVSF parameters including the ejection fraction, end-diastolic volume, and end-systolic volume. The introduction of cytoflavin to pati- ents led to (i) increase in the ejection fraction of left ventricle by 7.9% as compared to patients of the control group and (ii) decrease in the end-diastolic and end-systolic volume of the left ventricle on 7th day of hospitalization by 10.6% and 17.9%, respectively (p < 0.05). The addition of cytoflavin to standard the- rapy significantly reduced the level of troponin I on the 7th day in patients with acute myocardial infarction down to 81% relative to the control and the activity of creatine kinase by 35% (p < 0.05). The inclusion of cytoflavin in the treatment of patients with acute myocardial infarction should be considered as pathoge- netically proved, clinically justified, and promising therapy.

[EFFECT OF CITOFLAVIN ON THE PARAMETERS OF LIPID PEROXIDATION IN BLOOD PLASMA OF RATS UNDER COLD STRESS CONDITIONS.]

The possibility of correcting free radical oxidation of lipid membranes by the administration of cytoflavin was experimentally studied in rats. It is established that daily cold exposure for 3 h leads to increase in the level of lipid hydroperoxides, diene conjugates, and malonic dialdehyde on the background of decrease in activity of the antioxidant system in the blood of experimental animals. The introduction of cytoflavin (100 mg/kg, i.p.) for 21 day immediately prior to cold exposure leads to reliable (p < 0.05) decrease in the blood level of lipid hydroperoxides (by 13 - 21%), diene conjugates (by 24 - 25%), and malonic dialdehyde (by 20 - 33%) in comparison to rats of the control group. Analysis of the effect of cytoflavin on activity of the antioxidant system components showed that the level of ceruloplasmin and vitamin E in the blood of animals was reliably (p < 0.05) higher by 10 - 33% than analogous indicator in rats of the control group. Thus, the application of cytoflavin under conditions of long-term influence of cold on the organism of animals leads to stabilization of the processes of lipid peroxidation on the background of increased activity of the blood antioxidant system.